PHAXIAM Therapeutics S.A. (OTCPK: PXMT.F)
Health Care · Biotechnology · FR
$—
— today · — 1Y
PHAXIAM Therapeutics S.A. (OTCPK: PXMT.F) operates in the Biotechnology industry within the Health Care sector.
trading between 0.00 and 0.00.
Tweenvest scores PHAXIAM Therapeutics S.A. across four factors: quality 17/100. Its strongest factor is quality.
PXMT.F price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- $2.29M
- P/E
- —
- EPS
- —
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $0.00
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 68
- Next earnings
- —
About PHAXIAM Therapeutics S.A.
PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.
- ISIN
- FR001400K4B1
- Founded
- 2004
- Listed since
- May 7, 2013
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $266.69 | +0.82% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $446.73 | +0.65% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $148.14 | +0.95% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $554.91 | +1.34% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $839.98 | +1.39% |
| argenx SEENXTBR: ARGX | $63.06B | €877.40 | +1.53% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $157.65 | +13.51% |
Figures last refreshed Aug 18, 2026.